GleamWall
中文EN

PBM PSYENCE BIOMEDICAL LTD. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1985062 · Fiscal year ends 03/31

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY102.0%
TTM EPS YoY100.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA24.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets8.1%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income-3.69x
Accruals ratio112.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q2*2025-09-302025Q2*2024-09-302024Q2*2023-09-30
Income statement
Revenue———
R&D expense$357,444$265,626—
SG&A expense$217,225$243,044-$16,123
Interest expense$2,753$3,715$27,936
Pretax income-$1.50M-$1.16M—
Net income-$753,254$141,473-$309,682
EPS (basic)-0.514.07—
EPS (diluted)-0.514.07—
Weighted avg. shares (diluted)1.48M34,731—
Balance sheet
Cash & equivalents$7.15M$1.93M$605,480
Current assets$7.63M$2.24M—
PP&E, netmay include right-of-use assets (IFRS)$8,690$10,126—
Total assets$12.81M$2.25M—
Total liabilities$943,068$3.51M—
Shareholders' equity$11.87M-$1.26M-$982,671
Shares outstanding—605,789—
Cash flow statement
Operating cash flow———

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.